Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Orsay – page 18

3 415 clinical trials in Orsay, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Orsay at a glance
3 415
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 415 trials in Orsay

Open in trial search

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Safety and Tolerability of Alisertib Sodium and Paclitaxel in Patients with Small Cell Lung Cancer (Phase 2 Study)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alisertib Sodium
  • Sponsor:Puma Biotechnology Inc.

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:TRI-611
  • Sponsor:Triana Biomedicines Inc.

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Prostate cancer

Recruiting

Phase 1/2 First‑in‑Human Study of Oral GSK5471713B in Adults with Metastatic Castration‑Resistant Prostate Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GSK5471713B
  • Sponsor:Glaxosmithkline Research & Development Limited

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Orsay

What the registry says about research in the country

01 Neurological Studies

Advanced research focusing on neurological disorders including innovative imaging studies for epilepsy, multiple sclerosis, and Huntington's disease. These trials utilize cutting-edge PET-MRI technology to better understand disease progression and treatment effectiveness.

  • Drug-resistant epilepsy imaging
  • Multiple sclerosis inflammation markers
  • Huntington's disease biomarkers

Research aims to improve diagnostic accuracy and treatment planning through advanced imaging techniques.

02 Psychiatric & Mental Health

Innovative studies exploring treatments for mental health conditions, with a focus on early psychosis and severe depression. Trials evaluate novel therapeutic approaches combining medication and digital interventions.

  • Early psychosis treatment
  • Ketamine therapy for depression
  • Personalized care approaches

Research emphasizes personalized treatment strategies and innovative therapeutic combinations.

03 Critical Care Medicine

Studies addressing critical care challenges including septic shock management and specialized treatments for severe medical conditions. Focus on improving patient outcomes in intensive care settings.

  • Septic shock delirium prevention
  • Severe hyponatremia management
  • Ventilator-associated pneumonia

Trials aim to enhance treatment protocols in critical care scenarios.

04 Oncology & Imaging

Advanced research in cancer treatment and diagnostic imaging, particularly focusing on colorectal cancer and CNS lymphoma. Studies utilize innovative imaging techniques for better disease characterization.

  • Colorectal cancer therapy
  • CNS lymphoma imaging
  • PET/MR imaging applications

Research combines cutting-edge imaging with targeted therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.